Total Payments
$672,998
2024 Payments
$81,022
Companies
66
Transactions
2,390
Medicare Patients
4,253
Medicare Billing
$711,740
Payment Breakdown by Category
Other$586,379 (87.1%)
Food & Beverage$46,005 (6.8%)
Travel$29,603 (4.4%)
Consulting$10,419 (1.5%)
Education$591.28 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $586,329 | 446 | 87.1% |
| Food and Beverage | $46,005 | 1,634 | 6.8% |
| Travel and Lodging | $29,603 | 276 | 4.4% |
| Consulting Fee | $10,419 | 11 | 1.5% |
| Education | $591.28 | 22 | 0.1% |
| Long term medical supply or device loan | $49.95 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $252,086 | 566 | $0 (2024) |
| Lilly USA, LLC | $175,722 | 526 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $61,033 | 165 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47,501 | 151 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $44,636 | 132 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $43,277 | 165 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $22,119 | 57 | $0 (2024) |
| Amgen Inc. | $15,152 | 142 | $0 (2024) |
| Amarin Pharma Inc. | $865.17 | 49 | $0 (2022) |
| Dexcom, Inc. | $820.03 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $81,022 | 304 | Lilly USA, LLC ($48,887) |
| 2023 | $96,310 | 322 | Lilly USA, LLC ($49,667) |
| 2022 | $123,654 | 333 | Lilly USA, LLC ($57,736) |
| 2021 | $71,826 | 253 | Novo Nordisk Inc ($46,778) |
| 2020 | $39,070 | 243 | Novo Nordisk Inc ($17,996) |
| 2019 | $96,005 | 326 | Novo Nordisk Inc ($27,456) |
| 2018 | $93,622 | 335 | Novo Nordisk Inc ($34,599) |
| 2017 | $71,489 | 274 | Novo Nordisk Inc ($28,449) |
All Payment Transactions
2,390 individual payment records from CMS Open Payments — Page 1 of 96
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Automated insulin delivery system | ||||||
| 12/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Diabetes | ||||||
| 12/23/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $28.65 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $35.67 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $31.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Diabetes | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: DIABETES | ||||||
| 12/16/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Automated insulin delivery system | ||||||
| 12/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $56.86 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $16.08 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $28.58 | General |
| Category: Endocrinology | ||||||
| 12/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: Bone Health | ||||||
| 12/04/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/02/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: Diabetes | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Cardio-renal | ||||||
| 11/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $28.99 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 903 | 1,646 | $331,675 | $160,827 |
| 2022 | 10 | 1,053 | 1,913 | $385,775 | $188,746 |
| 2021 | 11 | 1,116 | 2,057 | $368,925 | $211,500 |
| 2020 | 11 | 1,181 | 1,861 | $287,805 | $150,667 |
Total Patients
4,253
Total Services
7,477
Medicare Billing
$711,740
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 420 | 946 | $212,850 | $109,947 | 51.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 179 | 235 | $47,000 | $18,999 | 40.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 71 | 95 | $14,250 | $7,330 | 51.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 107 | 227 | $22,700 | $6,937 | 30.6% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 27 | 29 | $8,700 | $4,509 | 51.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $8,400 | $4,268 | 50.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $8,775 | $3,888 | 44.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 16 | $4,000 | $2,675 | 66.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 38 | 50 | $5,000 | $2,275 | 45.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 427 | 977 | $219,825 | $115,588 | 52.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 227 | 321 | $64,200 | $26,490 | 41.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 81 | 112 | $16,800 | $8,939 | 53.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $15,200 | $7,721 | 50.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 105 | 235 | $23,500 | $7,294 | 31.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $14,300 | $6,520 | 45.6% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 36 | 39 | $11,700 | $6,187 | 52.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 58 | 110 | $11,000 | $5,219 | 47.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 16 | $4,000 | $2,687 | 67.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $5,250 | $2,102 | 40.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 422 | 1,058 | $207,100 | $127,175 | 61.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 207 | 305 | $53,500 | $25,789 | 48.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 142 | 198 | $29,650 | $16,141 | 54.4% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 58 | 63 | $16,250 | $10,627 | 65.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $13,350 | $7,306 | 54.7% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 96 | 188 | $15,625 | $6,112 | 39.1% |
About Dr. Cheng-Yang Tuan, MD
Dr. Cheng-Yang Tuan, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891746129.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cheng-Yang Tuan, MD has received a total of $672,998 in payments from pharmaceutical and medical device companies, with $81,022 received in 2024. These payments were reported across 2,390 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($586,329).
As a Medicare-enrolled provider, Tuan has provided services to 4,253 Medicare beneficiaries, totaling 7,477 services with total Medicare billing of $711,740. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location San Francisco, CA
- Active Since 05/12/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891746129
Products in Payments
- MOUNJARO (Drug) $135,775
- JARDIANCE (Drug) $78,928
- Rybelsus (Drug) $71,899
- Ozempic (Drug) $53,878
- RYBELSUS (Drug) $49,687
- INVOKANA (Drug) $43,249
- FARXIGA (Drug) $39,050
- Tresiba (Drug) $26,081
- Kerendia (Drug) $22,119
- TOUJEO (Drug) $16,520
- Xultophy 100/3.6 (Drug) $16,299
- Victoza (Drug) $15,733
- Repatha (Biological) $13,250
- SOLIQUA 100/33 (Drug) $12,026
- TOUJEO (Biological) $10,894
- SOLIQUA 100/33 (Biological) $10,825
- SOLIQUA (Drug) $10,397
- BYDUREON (Drug) $5,254
- TRULICITY (Drug) $1,427
- EVENITY (Biological) $1,300
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in San Francisco
Dr. Nancy Bohannon, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $265,062
Endocrinology, Diabetes & Metabolism $265,062
Lewis Blevins, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $158,184
Endocrinology, Diabetes & Metabolism $158,184
Dr. Wade Aubry, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $104,039
Endocrinology, Diabetes & Metabolism $104,039
Dr. Jennifer Perkins, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $84,954
Endocrinology, Diabetes & Metabolism $84,954
Dr. Daniel Bikle, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $23,160
Endocrinology, Diabetes & Metabolism $23,160
Dr. Eric Buxton, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $10,839
Endocrinology, Diabetes & Metabolism $10,839